-transparent.png){kind=logo}
N-Trifluoroacetyladriamycin-14-valerate differs from Adriamycin in its rapid intracellular transport and lack of fluorescent binding to nuclei or chromosomes. Both of these anthracyclines cause inhibition in the incorporation of labeled precursors into nucleic acids, extensive chromosomal damage, and arrest of cell cycle traverse in G2. In human lymphoid cells, N-trifluoroacetyladriamycin-14-valerate, unlike Adriamycin, does not show cell cycle phase-specific or proliferation-related cytotoxic effects. In an L1210 soft-agar assay, both Adriamycin and N-trifluoroacetyladriamycin-14-valerate show no enhanced sensitivity of mid-S-phase cells to their cytotoxic action.
Related Publications
A Krishan, and
K Dutt, and
M Israel, and
R Ganapathi
January 1978,
Cancer treatment reports,
A Krishan, and
K Dutt, and
M Israel, and
R Ganapathi
January 1983,
European journal of cancer & clinical oncology,
A Krishan, and
K Dutt, and
M Israel, and
R Ganapathi
September 1980,
Canadian journal of biochemistry,
A Krishan, and
K Dutt, and
M Israel, and
R Ganapathi
June 1976,
Cancer research,
A Krishan, and
K Dutt, and
M Israel, and
R Ganapathi
February 1978,
Cancer research,
A Krishan, and
K Dutt, and
M Israel, and
R Ganapathi
March 1978,
The Journal of pharmacology and experimental therapeutics,
A Krishan, and
K Dutt, and
M Israel, and
R Ganapathi
May 1979,
Cancer treatment reports,
A Krishan, and
K Dutt, and
M Israel, and
R Ganapathi
January 1987,
Cancer chemotherapy and pharmacology,
A Krishan, and
K Dutt, and
M Israel, and
R Ganapathi
April 1985,
Teratology,
A Krishan, and
K Dutt, and
M Israel, and
R Ganapathi
April 1987,
Cancer research,
